RedoxTherapies, a privately held company founded by Michail Sitkovsky, Ph.D., aims to overcome the inhibition of tumor-reactive T cells by utilizing A2 adenosine antagonists. These antagonists, such as vipadenant, a potent and selective A2a adenosine receptor antagonist, are combined with immuno-modulatory agents. RedoxTherapies has acquired exclusive licenses and intellectual property in this field, positioning itself as a key player in the development of innovative cancer therapies.